Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan

Yoshihiro Shibata, hiroshi ariyama, Eishi Baba, Yasushi Takii, Taito Esaki, Kenji Mitsugi, Tanji Tsuchiya, Hitoshi Kusaba, Koichi Akashi, Shuji Nakano

研究成果: ジャーナルへの寄稿記事

29 引用 (Scopus)

抄録

Background: Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC. With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities. Methods: In order to clarify the clinical features of allergic reactions to oxaliplatin, we retrospectively investigated CRC patients who had received oxaliplatin-based chemotherapies. Results: One hundred and twenty-five CRC patients who had been treated with FOLFOX regimens (containing oxaliplatin, 5-FU, and LV) were examined, and 21 patients (17%) were found to have developed allergic reactions. Sixteen patients (13%) had grade 1/2 adverse events, classified according to the common terminology criteria for adverse events (CTC-AE) version 3.0 and 5 (4%) had grade 3/4 adverse events. The allergic reaction appeared after a median number of nine cycles (range, 2-15 cycles). Previous chemotherapy included 5-FU/LV, CPT-11, and S-1. All of the patients with allergic reactions recovered completely when treated with antiallergy drugs. Oxaliplatin was reintroduced in 11 patients, with the use of prophylactic agents; allergic reaction to the reintroduction was not observed in 8 patients and grade 1/2 allergic reactions developed in 3 patients. No correlation was identified between allergic reaction and patients' background characteristics such as sex, history of allergy, and profile of other adverse events. Conclusion: Allergic reactions to oxaliplatin remain an important issue for patients being able to safely continue effective chemotherapies; further analysis will be needed to establish methods for the prediction and prophylaxis of such reactions.

元の言語英語
ページ(範囲)397-401
ページ数5
ジャーナルInternational Journal of Clinical Oncology
14
発行部数5
DOI
出版物ステータス出版済み - 10 1 2009

Fingerprint

oxaliplatin
Colorectal Neoplasms
Japan
Hypersensitivity
Leucovorin
Fluorouracil
irinotecan
Drug Therapy
Platinum Compounds

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

これを引用

Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. / Shibata, Yoshihiro; ariyama, hiroshi; Baba, Eishi; Takii, Yasushi; Esaki, Taito; Mitsugi, Kenji; Tsuchiya, Tanji; Kusaba, Hitoshi; Akashi, Koichi; Nakano, Shuji.

:: International Journal of Clinical Oncology, 巻 14, 番号 5, 01.10.2009, p. 397-401.

研究成果: ジャーナルへの寄稿記事

Shibata, Yoshihiro ; ariyama, hiroshi ; Baba, Eishi ; Takii, Yasushi ; Esaki, Taito ; Mitsugi, Kenji ; Tsuchiya, Tanji ; Kusaba, Hitoshi ; Akashi, Koichi ; Nakano, Shuji. / Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. :: International Journal of Clinical Oncology. 2009 ; 巻 14, 番号 5. pp. 397-401.
@article{7370aa39b69644f3b1b256332475fe57,
title = "Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan",
abstract = "Background: Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC. With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities. Methods: In order to clarify the clinical features of allergic reactions to oxaliplatin, we retrospectively investigated CRC patients who had received oxaliplatin-based chemotherapies. Results: One hundred and twenty-five CRC patients who had been treated with FOLFOX regimens (containing oxaliplatin, 5-FU, and LV) were examined, and 21 patients (17{\%}) were found to have developed allergic reactions. Sixteen patients (13{\%}) had grade 1/2 adverse events, classified according to the common terminology criteria for adverse events (CTC-AE) version 3.0 and 5 (4{\%}) had grade 3/4 adverse events. The allergic reaction appeared after a median number of nine cycles (range, 2-15 cycles). Previous chemotherapy included 5-FU/LV, CPT-11, and S-1. All of the patients with allergic reactions recovered completely when treated with antiallergy drugs. Oxaliplatin was reintroduced in 11 patients, with the use of prophylactic agents; allergic reaction to the reintroduction was not observed in 8 patients and grade 1/2 allergic reactions developed in 3 patients. No correlation was identified between allergic reaction and patients' background characteristics such as sex, history of allergy, and profile of other adverse events. Conclusion: Allergic reactions to oxaliplatin remain an important issue for patients being able to safely continue effective chemotherapies; further analysis will be needed to establish methods for the prediction and prophylaxis of such reactions.",
author = "Yoshihiro Shibata and hiroshi ariyama and Eishi Baba and Yasushi Takii and Taito Esaki and Kenji Mitsugi and Tanji Tsuchiya and Hitoshi Kusaba and Koichi Akashi and Shuji Nakano",
year = "2009",
month = "10",
day = "1",
doi = "10.1007/s10147-009-0883-6",
language = "English",
volume = "14",
pages = "397--401",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan

AU - Shibata, Yoshihiro

AU - ariyama, hiroshi

AU - Baba, Eishi

AU - Takii, Yasushi

AU - Esaki, Taito

AU - Mitsugi, Kenji

AU - Tsuchiya, Tanji

AU - Kusaba, Hitoshi

AU - Akashi, Koichi

AU - Nakano, Shuji

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background: Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC. With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities. Methods: In order to clarify the clinical features of allergic reactions to oxaliplatin, we retrospectively investigated CRC patients who had received oxaliplatin-based chemotherapies. Results: One hundred and twenty-five CRC patients who had been treated with FOLFOX regimens (containing oxaliplatin, 5-FU, and LV) were examined, and 21 patients (17%) were found to have developed allergic reactions. Sixteen patients (13%) had grade 1/2 adverse events, classified according to the common terminology criteria for adverse events (CTC-AE) version 3.0 and 5 (4%) had grade 3/4 adverse events. The allergic reaction appeared after a median number of nine cycles (range, 2-15 cycles). Previous chemotherapy included 5-FU/LV, CPT-11, and S-1. All of the patients with allergic reactions recovered completely when treated with antiallergy drugs. Oxaliplatin was reintroduced in 11 patients, with the use of prophylactic agents; allergic reaction to the reintroduction was not observed in 8 patients and grade 1/2 allergic reactions developed in 3 patients. No correlation was identified between allergic reaction and patients' background characteristics such as sex, history of allergy, and profile of other adverse events. Conclusion: Allergic reactions to oxaliplatin remain an important issue for patients being able to safely continue effective chemotherapies; further analysis will be needed to establish methods for the prediction and prophylaxis of such reactions.

AB - Background: Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC. With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities. Methods: In order to clarify the clinical features of allergic reactions to oxaliplatin, we retrospectively investigated CRC patients who had received oxaliplatin-based chemotherapies. Results: One hundred and twenty-five CRC patients who had been treated with FOLFOX regimens (containing oxaliplatin, 5-FU, and LV) were examined, and 21 patients (17%) were found to have developed allergic reactions. Sixteen patients (13%) had grade 1/2 adverse events, classified according to the common terminology criteria for adverse events (CTC-AE) version 3.0 and 5 (4%) had grade 3/4 adverse events. The allergic reaction appeared after a median number of nine cycles (range, 2-15 cycles). Previous chemotherapy included 5-FU/LV, CPT-11, and S-1. All of the patients with allergic reactions recovered completely when treated with antiallergy drugs. Oxaliplatin was reintroduced in 11 patients, with the use of prophylactic agents; allergic reaction to the reintroduction was not observed in 8 patients and grade 1/2 allergic reactions developed in 3 patients. No correlation was identified between allergic reaction and patients' background characteristics such as sex, history of allergy, and profile of other adverse events. Conclusion: Allergic reactions to oxaliplatin remain an important issue for patients being able to safely continue effective chemotherapies; further analysis will be needed to establish methods for the prediction and prophylaxis of such reactions.

UR - http://www.scopus.com/inward/record.url?scp=70350508569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350508569&partnerID=8YFLogxK

U2 - 10.1007/s10147-009-0883-6

DO - 10.1007/s10147-009-0883-6

M3 - Article

VL - 14

SP - 397

EP - 401

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -